Efficacy and safety of infliximab in patients with rheumatoid arthritis

Wen Zhang, Qun Shi, Dong Hai Wu, Chun De Bao, Nan Ping Yang, Zhan Guo Li, Ping Zhu, Xiao Zhang, Ci Bo Huang, Dong Yi He, Zhi Zhong Ye, Yi Tao, Yong Fei Fang, Jie Ruo Gu, Hua Xiang Wu, Ling Yun Sun, Xiu Yan Yang, Feng Huang, Hu Ji Xu, Dong Bao ZhaoMiao Jia Zhang, Yi Zheng, Mai Xing Ai, Jun Lu, Feng Chun Zhang

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Objective: To investigate the efficacy and safety of Infliximab (IFX) plus methotrexate (MTX) combination therapy in patients with rheumatoid arthritis (RA). Methods: Prospectively observe refractory RA patients who were treated with combination therapy of MTX and IFX. IFX was infused at the dosage of 3 mg/kg, in week 0, 2, 6, and then every 8 weeks. During treatment, clinical variables, disease activity and adverse effects were evaluated. Results: After treatment, 69.8%, 52.4%, 29.5% and 7.2% RA patients achieved ACR20, ACR50, ACR70 and ACR90 respectively. There were significant statistical differences in the changes of swollen joint counts, tender joint counts, VAS scale, patient's global assessment, and physician's global assessment before and after therapy. Conclusion: Infliximab plus MTX achieved significant efficacy and safety in refractory RA patients.

Original languageEnglish
Pages (from-to)1876-1880
Number of pages5
JournalNational Medical Journal of China
Issue number27
StatePublished - 21 Jul 2009
Externally publishedYes


  • Methotrexate
  • Rheumatoid arthritis
  • TNF inhibitor


Dive into the research topics of 'Efficacy and safety of infliximab in patients with rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this